Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate

J Cancer Res Clin Oncol. 1992;118(8):565-6. doi: 10.1007/BF01211796.

Abstract

A 60-year-old woman with gastric cancer had undergone partial gastrectomy in September 1989. Pathological examination revealed a poorly differentiated adenocarcinoma of pT3pN3pM0 (not resected for cure), stage IV. Postoperative adjuvant therapy comprised 1-(tetrahydro-2-furanyl)-5-fluorouracil plus uracil and OK-432. On 11 August 1990, two forefinger-tip-sized tumors were palpated beneath the operation scar. They increase in size, the superior tumor reaching 4x3 cm, the inferior tumor 5x3 cm on 5 September. Then, on 17 September, the inferior tumor was resected but the superior tumor remained; the histological type was poorly differentiated adenocarcinoma. After the operation, from 20 September, she was given 4 mg irsogladine maleate orally every day. On 8 October, there was no increase in the size of the superior tumor. By 29 October, the superior tumor had disappeared and no further tumor appeared thereafter; the patient showed no sign of relapse.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Neoplasms / drug therapy*
  • Abdominal Neoplasms / secondary*
  • Abdominal Neoplasms / surgery
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / secondary
  • Adenocarcinoma / surgery
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Middle Aged
  • Mitomycin / administration & dosage
  • Remission Induction / methods
  • Stomach Neoplasms / pathology*
  • Triazines / administration & dosage
  • Triazines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Triazines
  • Mitomycin
  • irsogladine
  • Fluorouracil